Skip to main content
Premium Trial:

Request an Annual Quote

Galapagos Genomics Splits Business into Drug Discovery, Service Units

NEW YORK, Sept. 22 (GenomeWeb News) - Galapagos Genomics has split its business into a drug discovery and a research service unit, the Mechelen, Belgium-based company said today.

 

The service unit will operate under the name Galadeno from the company's facility in Leiden. It will offer both individual adenovirus-based siRNA and full-length gene reagents for drug target discovery and validation. Galadeno will also provide access to its cDNA collection FlexSelect and its siRNA collection SilenceSelect, and will continue to offer a human primary cell-based functional screening platform to partners.

 

The drug discovery business will continue to operate under the name Galapagos and will be located at the company's Mechelen facility.

 

"[T]his separation will allow each unit to grow in a dedicated way," said Galapagos CEO Onno van de Stolpe in a statement.

The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.